Notably, Kumar et al. reported that a high-affinity PD-L1-specific peptide (WL12) radiolabeled with 64Cu, was able to measure the PD-L1 engagement of each therapeutic antibody at the tumor, independently of its biophysical characteristics and in vivo kinetics [69]. This evidence concerns the gene CD274 and neoplasm.